

10/537851 #5

05 MAY 2006

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))Docket No.
RLI-270US

In Re Application Of: MEHTA et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/537,851	12/10/2002	TBA	26815	TBA	

Title:

DISUBSTITUTED AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Address to:

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450****37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);**OR**☐ the fee set forth in 37 CFR 1.17(p).**BEST AVAILABLE COPY**

P10A/REV05

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLI-270US

In Re Application of: **MEHTA**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/537,851	12/10/2002	TBA	26815	TBA	

Title:

DISUBSTITUTED AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912
as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by ~~First-Class~~ ^{Express} Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as ^{first class} mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Michelle Kagen

Signature of Person Mailing Correspondence

MICHELLE MORGAN

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Dated: May 5, 2006

George E. Heibel, Esq.
Reg. No. 42,648
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Tel.: 609 720-5334
Fax: 609 514-9779

CC:

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-270US	Serial No.: 10/537,851
	Applicants: MEH <i>et al.</i>	
	Filed: 6/8/2005	Group:

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	3,176,019	3/30/1965	Campbell <i>et al.</i>	260	293.4	
	A2	5,281,601	1/25/1994	Cross <i>et al.</i>	514	320	
	A3	5,397,800	3/14/1995	Alker <i>et al.</i>	514	413	
	A4	5,703,091	12/30/1997	Steiner <i>et al.</i>	514	300	
	A5	5,914,338	6/22/1999	Jeppesen <i>et al.</i>	514	362	
	A6	5,948,792	9/7/1999	Tsuchiya <i>et al.</i>	514	317	
	A7	6,130,232	10/10/2000	Mase <i>et al.</i>	514	318	
	A8	6,174,900	1/16/2001	Okada <i>et al.</i>	514	317	

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	EP 0 132 130	1/23/1985	EPO	C07D	307/79	
	B2	EP 0 325 571	7/26/1989	EPO	C07C	215/54	
	B3	EP 0 388 054	9/19/1990	EPO	C07D	207/08	
	B4	EP 0 801 067	10/15/1997	EPO	C07D	453/02	
	B5	EP 0 823 423	2/11/1998	EPO	C07D	211/46	
	B6	EP 0 863 141	9/9/1998	EPO	C07D	401/06	
	B7	EP 0 930 298	7/21/199	EPO	C07D	211/46	
	B8	GB 940,540	10/30/1963	UK	C07C		
	B9	JP 135958/1994	5/17/1994	Japan	C07D	333/16	
	B10	JP 92921/1994	4/5/1994	Japan	C07C	237/20	
	B11	WO 91/09013	6/27/1991	PCT	C07D	207/08	
	B12	WO 93/16018	8/19/1993	PCT	C05F	17/02	
	B13	WO 93/16048	8/19/1993	PCT	C07D	211/26	Equivalent CA 2155320

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-270US

Serial No.: 10/537,851

Applicants: MEH  et al.

Filed: 6/8/2005

Group:

	B14	WO 96/33973	10/31/1996	PCT	C07D	211/46	Equivalent EP 0 823 423
	B15	WO 97/45414	12/4/1997	PCT	C07D	211/58	Abstract
	B16	WO 98/05641	2/12/1998	PCT	C07D	211/46	Equivalent US 5,948,792
	B17	WO 98/29402	7/9/1998	PCT	C07D	311/20	
	B18	WO 04/004629	1/15/2004	PCT	A61K		
	B19	WO 04/005252	1/15/2004	PCT	C07D	209/52	


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , 323(2):411-416 (1986)					
	C2	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , 237:527-531 (1987)					
	C3	Eglen et al., "Muscarinic receptor ligands and their therapeutic potential", <i>Current Opinion in Chemical Biology</i> , 3:426-432 (1999)					
	C4	Eglen et al., "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , 22(8):409-414 (2001)					
	C5	Felder et al., "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , 43(23):4333-4353 (2000)					
	C6	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , 6:142-193 (2001)					
	C7	Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , 22(5):215-219 (2001)					
	C8	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , 41:691-721 (2001)					
	C9	Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , 2(3):268-282 (2000)					
	C10	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , 55(Suppl. 5A):33-46 (2000)					
	C11	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)					
	C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3 Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , 45:984-987 (2002)					
	C13	Vogel's textbook, "Practical Organic Chemistry" 1046-1047 (5th Ed.)					

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-270US	Serial No.: 10/537,851
	Applicants: MEH  et al.	
	Filed: 6/8/2005	Group:

C14	Braish et al., "Construction of the (1 α ,5 α ,6 α)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", <i>Synlett</i> , 1100-1102 (1996)
C15	Vogel's textbook, "Practical Organic Chemistry" 1048-1051 (5th Ed.)
C16	Shacklett and Smith, "The Preparation of Substituted Benzilic Acids", <i>Journal of the American Chemical Society</i> , <u>75</u> :2654-2657 (1953)
C17	Gotteland et al., "(Aryloxy)methylsilane Derivatives as New Cholesterol Biosynthesis Inhibitors: Synthesis and Hypocholesterolemic Activity of a New Class of Squalene Epoxidase Inhibitors", <i>Journal of Medicinal Chemistry</i> , <u>38</u> :3207-3216 (1995)
C18	Weinstock et al., "A General, One-Step Synthesis of α -keto Esters", <i>Synthetic Communications</i> , <u>11</u> (12):943-946 (1981)
C19	Cornforth et al., "General Synthetic Routes to β -Hydroxy-acids from t-Butyl Esters and the Reformatskii Reaction", <i>Journal of the Chemical Society C</i> , <u>20</u> :2799-2805 (1969)
C20	Grover et al., "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis", <i>Journal of Organic Chemistry</i> , <u>65</u> :6283-6287 (2000)
C21	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , <u>64</u> (25):2351-2358 (1999)
C22	Cheng and Prusoff, "Relationship between the inhibition constant (K_1) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , <u>22</u> :3099-3108 (1973)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	